Arvinas (ARVN) vs Assembly Biosciences (ASMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Assembly Biosciences (ASMB) has outperformed Arvinas (ARVN) over the past year, losing 3.8% versus a loss of 23.0%. Over five years, ASMB leads with a -41.3% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($484.6 million vs $464.6 million), about 1.0 times the size.
On valuation, Assembly Biosciences trades at a lower trailing P/E (21.9x vs 28.9x for Arvinas).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | ASMB |
|---|---|---|
| Share price | $7.51 | $22.82 |
| Market cap | $484.55M | $464.63M |
| 1-day change | +0.81% | -0.57% |
| YTD return | -36.68% | -32.52% |
| 1-year return | -22.97% | -3.81% |
| 5-year return | -91.18% | -41.33% |
| P/E ratio (TTM) | 28.88 | 21.94 |
| EPS (TTM) | $0.26 | $1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $39.71 |
| 52-week low | $6.97 | $21.80 |
| Distance from 52-week high | -48.24% | -42.53% |
| Analyst consensus | buy | none |
| Avg. price target upside | +85.49% | +127.87% |
| Average volume | 788.21K | 279.78K |
| Shares outstanding | 64.52M | 20.36M |
| Employees | 246 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASMB has outperformed ARVN by 19.2 percentage points over the past year.
- Arvinas trades at a higher earnings multiple (28.9x vs 21.9x trailing P/E).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
ARVN vs ASMB FAQ
Which is bigger, Arvinas or Assembly Biosciences?
Arvinas (ARVN) is larger, with a market capitalization of $484.55M compared with $464.63M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ARVN or ASMB?
ASMB returned -3.81% over the past 12 months, compared with -22.97% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARVN or ASMB?
ASMB has the lower trailing P/E at 21.9, versus 28.9 for ARVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arvinas and Assembly Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.